The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Board of Directors
    • Our Staff & Volunteers
    • The Antibody Society’s Standing Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Executive Committee
      • Finance & Audit Committee
      • Governance & Nominating Committee
      • Initiatives Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2022
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2022
    • FOCIS Symposia
  • AIRR Community
    • AIRR-C 2022 Votes
    • AIRR News
    • AIRR Community Service Prize 2022
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • James S. Huston Antibody Science Talent Award
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Research Competitions
    • Science Writing Competition
      • Science Writing Competition Winners
    • Discount codes for meeting registration
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Antibody News You Should Know

Antibody News You Should Know

Antibody-based therapeutics are advancing in clinical development at a rapid rate and being approved in record numbers.

To keep our members up to date on recent events, we compile relevant information from news releases and other sources, and send this “Antibody News You Should Know” to our members via email twice per month. We include news about:

  • Clinical studies started recently, focusing on the first Phase 1, Phase 2 or Phase 3 study
  • Submission of marketing applications
  • Marketing approvals
  • Licensing deals
  • Regulatory agency designations granted (e.g., Orphan Drug, PRIME, Breakthrough Therapy, Priority review)

Since March 15, 2020, we have included in-depth coverage of news related to COVID-19 biologic interventions.

As a service to the community, The Antibody Society offers past “Antibody News You Should Know”, which can be accessed via links below. The PDFs include links to the original source and can be searched by keywords (e.g., SARS-CoV-2, bispecific, antibody-drug conjugate).

2022 Antibody News You Should Know

View PDF of Antibody News from Q1 2022 (Jan-Mar).

 


2021 Antibody News You Should Know

View PDF of Antibody News from Q4 2021 (Oct-Dec).

View PDF of Antibody News from Q3 2021 (Jul-Sep).

View PDF of Antibody News from Q2 2021 (Apr-Jun).

View PDF of Antibody News from Q1 2021 (Jan-Mar).


2020 Antibody News You Should Know

View PDF of Antibody News from H2 2020 (Jul-Dec).

View PDF of Antibody News from Q2 2020 (Apr-Jun).

View PDF of Antibody News from Q1 2020 (Jan-Mar).


2019 Antibody News You Should Know

View PDF of Antibody News from Apr 15-Dec 31, 2019

If you are not a Society member, please register to receive quarterly Antibody News delivered by email.

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • 2022 Science Writing Competition winners announced! May 15, 2022
  • Our Antibody Research Competition is open! May 4, 2022
  • Biologics Developability: Call for Papers May 2, 2022

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Board of Directors
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals